Jess Armor, MD
Hematology & Oncology · Oklahoma City, OKNPI 1922059666
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.9%), other and education — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Novartis at 50.8% of the total.
Across 227 payments — averaging $27.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Pfizer$477
- AstraZeneca$265
- Genentech USA, Inc.$264
- Astellas Pharma US Inc$220
- Beone Medicines USA, Inc.$190
- plus $2K from 33 others
Across 4 payments — averaging $1450.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$6K
What the payments were for
- Food & beverage$2,98248%
- Education$5759%
- Other$2,66543%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 60 | $3,158 |
| Pfizer | 32 | $477 |
| AstraZeneca(2 entities) | 5 | $265 |
| Genentech USA, Inc. | 14 | $264 |
| Astellas Pharma US Inc | 8 | $220 |
| Beone Medicines USA, Inc. | 11 | $190 |
| Merck | 9 | $173 |
| E.r. Squibb & Sons, L.L.C. | 9 | $161 |
| Array Biopharma Inc | 9 | $140 |
| Bristol Myers Squibb | 8 | $129 |
| Johnson & Johnson | 5 | $99 |
| Gilead(2 entities) | 6 | $95 |
| AbbVie | 5 | $80 |
| Beigene USA, Inc. | 6 | $78 |
| EMD Serono, Inc. | 3 | $67 |
| Ipsen Biopharmaceuticals, Inc | 4 | $65 |
| Sanofi | 4 | $64 |
| Eisai Inc. | 3 | $60 |
| Amgen | 3 | $57 |
| Daiichi Sankyo Inc. | 2 | $40 |
| ADC Therapeutics America, Inc. | 2 | $39 |
| G1 Therapeutics, Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $21 |
| Morphosys, US Inc. | 1 | $21 |
| Sobi, Inc | 1 | $19 |
| Seagen Inc. | 1 | $18 |
| Bayer | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Incyte Corporation | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Verastem, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
| Dendreon Pharmaceuticals LLC | 1 | $13 |
| Sun Pharmaceutical Industries Inc. | 1 | $12 |
| Tolmar Pharmaceuticals, Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,222 in reported general payments places this provider in the 75th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 106 | $1,453,987 |
| BrukinsaZanubrutinib | 63 | $934,071 |
| JakafiRuxolitinib Phosphate | 50 | $816,847 |
| RevlimidLenalidomide | 41 | $675,195 |
| TagrissoOsimertinib Mesylate | 36 | $576,430 |
| XtandiEnzalutamide | 34 | $478,517 |
| CalquenceAcalabrutinib Maleate | 24 | $348,184 |
| GleevecImatinib Mesylate | 17 | $225,631 |
| KisqaliRibociclib Succinate | 15 | $220,341 |
| NubeqaDarolutamide | 12 | $153,119 |
| VenclextaVenetoclax | 16 | $152,500 |
| RetevmoSelpercatinib | 13 | $142,863 |
| XalkoriCrizotinib | 13 | $139,510 |
| EliquisApixaban | 124 | $101,025 |
| InqoviDecitabine/Cedazuridine | 12 | $99,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $78 | $934,07163 claims |
| AstraZenecaTagrisso, Calquence | $265 | $924,61460 claims |
| Incyte CorporationJakafi | $15 | $816,84750 claims |
| Bristol Myers SquibbRevlimid | $129 | $675,19541 claims |
| Astellas Pharma US IncXtandi | $220 | $478,51734 claims |
| NovartisGleevec, Kisqali | $3,158 | $445,97332 claims |
| PfizerXalkori, Eliquis | $477 | $240,535137 claims |
| BayerNubeqa | $15 | $153,11912 claims |
| AbbVieVenclexta | $80 | $152,50016 claims |
| Johnson & JohnsonXarelto | $99 | $8,91216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.